Subsets of lung cancers and glioblastomas harbor activated point mutants or splice variants of EGFR, but such alterations are rare in breast cancer where EGFR is activated primarily by overexpression of the wild type protein [28]. This evidence concerns the gene EGFR and glioblastoma.